FDA Approves Genentech ’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema
Approval is based on two Phase III studies demonstrating early and sustained vision improvements that were...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Age-Related Macular Degeneration (AMD) | Diabetes | Drugs & Pharmacology | Endocrinology | Study | Vitamin A